Posted by Michael Wonder on 23 Jan 2017
Bristol-Myers Squibb provides regulatory update in first-line lung cancer
19 January 2017 - All first-line lung registrational studies continue.
Bristol-Myers Squibb announced today that it has decided not to pursue an accelerated regulatory pathway for the combination of Opdivo plus Yervoy in first-line lung cancer in the U.S. based on a review of data available at this time.
In order to protect the integrity of ongoing registrational studies, the company will not be providing additional details.
